Cargando…
Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data
PURPOSE: Real-world evidence on the impact of forced expiratory volume in one second (FEV(1)) and exacerbations on health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) is sparse especially with regard to GOLD ABCD groups. This study investigates how ch...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473986/ https://www.ncbi.nlm.nih.gov/pubmed/34588773 http://dx.doi.org/10.2147/COPD.S313711 |
_version_ | 1784575120367419392 |
---|---|
author | Stöber, Alisa Lutter, Johanna I Schwarzkopf, Larissa Kirsch, Florian Schramm, Anja Vogelmeier, Claus F Leidl, Reiner |
author_facet | Stöber, Alisa Lutter, Johanna I Schwarzkopf, Larissa Kirsch, Florian Schramm, Anja Vogelmeier, Claus F Leidl, Reiner |
author_sort | Stöber, Alisa |
collection | PubMed |
description | PURPOSE: Real-world evidence on the impact of forced expiratory volume in one second (FEV(1)) and exacerbations on health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) is sparse especially with regard to GOLD ABCD groups. This study investigates how changes in FEV(1) and exacerbations affect generic and disease-specific HRQoL in COPD patients over one year. METHODS: Using German claims data and survey data, we classified 3016 COPD patients and analyzed their health status by GOLD groups AB and CD. HRQoL was measured with the disease-specific COPD assessment test (CAT) and the visual analog scale (VAS) from the generic Euro-Qol 5D-5L. We applied change score models to assess associations between changes in FEV(1) (≥100 mL decrease/no change/≥100 mL increase) or the development of severe exacerbations with change in HRQoL. RESULTS: FEV(1) decrease was associated with a significant but not minimal important difference (MID) deterioration in disease-specific HRQoL (mean change [95% CI]: CAT +0.74 [0.15 to 1.33]), while no significant change was observed in the generic VAS. Experiencing at least one severe exacerbation also had a significant impact on CAT deterioration (+1.58 [0.52 to 2.64]), but again not on VAS. Here, GOLD groups AB showed not only a statistically but also a clinically relevant MID deterioration in CAT (+2.1 [0.88 to 3.32]). These particular patient groups were further characterized by a higher probability of being male, having a higher mMRC and Charlson index, and a lower probability of having higher FEV(1) or BMI values. CONCLUSION: FEV(1) decline and the occurrence of ≥1 severe exacerbation are significantly associated with overall deterioration in disease-specific HRQoL. Preventing severe exacerbations particularly in patients without previous severe exacerbations (ABCD groups A and B) may help to stabilize the key patient-reported outcome HRQoL. |
format | Online Article Text |
id | pubmed-8473986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-84739862021-09-28 Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data Stöber, Alisa Lutter, Johanna I Schwarzkopf, Larissa Kirsch, Florian Schramm, Anja Vogelmeier, Claus F Leidl, Reiner Int J Chron Obstruct Pulmon Dis Original Research PURPOSE: Real-world evidence on the impact of forced expiratory volume in one second (FEV(1)) and exacerbations on health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) is sparse especially with regard to GOLD ABCD groups. This study investigates how changes in FEV(1) and exacerbations affect generic and disease-specific HRQoL in COPD patients over one year. METHODS: Using German claims data and survey data, we classified 3016 COPD patients and analyzed their health status by GOLD groups AB and CD. HRQoL was measured with the disease-specific COPD assessment test (CAT) and the visual analog scale (VAS) from the generic Euro-Qol 5D-5L. We applied change score models to assess associations between changes in FEV(1) (≥100 mL decrease/no change/≥100 mL increase) or the development of severe exacerbations with change in HRQoL. RESULTS: FEV(1) decrease was associated with a significant but not minimal important difference (MID) deterioration in disease-specific HRQoL (mean change [95% CI]: CAT +0.74 [0.15 to 1.33]), while no significant change was observed in the generic VAS. Experiencing at least one severe exacerbation also had a significant impact on CAT deterioration (+1.58 [0.52 to 2.64]), but again not on VAS. Here, GOLD groups AB showed not only a statistically but also a clinically relevant MID deterioration in CAT (+2.1 [0.88 to 3.32]). These particular patient groups were further characterized by a higher probability of being male, having a higher mMRC and Charlson index, and a lower probability of having higher FEV(1) or BMI values. CONCLUSION: FEV(1) decline and the occurrence of ≥1 severe exacerbation are significantly associated with overall deterioration in disease-specific HRQoL. Preventing severe exacerbations particularly in patients without previous severe exacerbations (ABCD groups A and B) may help to stabilize the key patient-reported outcome HRQoL. Dove 2021-09-21 /pmc/articles/PMC8473986/ /pubmed/34588773 http://dx.doi.org/10.2147/COPD.S313711 Text en © 2021 Stöber et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Stöber, Alisa Lutter, Johanna I Schwarzkopf, Larissa Kirsch, Florian Schramm, Anja Vogelmeier, Claus F Leidl, Reiner Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data |
title | Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data |
title_full | Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data |
title_fullStr | Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data |
title_full_unstemmed | Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data |
title_short | Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data |
title_sort | impact of lung function and exacerbations on health-related quality of life in copd patients within one year: real-world analysis based on claims data |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473986/ https://www.ncbi.nlm.nih.gov/pubmed/34588773 http://dx.doi.org/10.2147/COPD.S313711 |
work_keys_str_mv | AT stoberalisa impactoflungfunctionandexacerbationsonhealthrelatedqualityoflifeincopdpatientswithinoneyearrealworldanalysisbasedonclaimsdata AT lutterjohannai impactoflungfunctionandexacerbationsonhealthrelatedqualityoflifeincopdpatientswithinoneyearrealworldanalysisbasedonclaimsdata AT schwarzkopflarissa impactoflungfunctionandexacerbationsonhealthrelatedqualityoflifeincopdpatientswithinoneyearrealworldanalysisbasedonclaimsdata AT kirschflorian impactoflungfunctionandexacerbationsonhealthrelatedqualityoflifeincopdpatientswithinoneyearrealworldanalysisbasedonclaimsdata AT schrammanja impactoflungfunctionandexacerbationsonhealthrelatedqualityoflifeincopdpatientswithinoneyearrealworldanalysisbasedonclaimsdata AT vogelmeierclausf impactoflungfunctionandexacerbationsonhealthrelatedqualityoflifeincopdpatientswithinoneyearrealworldanalysisbasedonclaimsdata AT leidlreiner impactoflungfunctionandexacerbationsonhealthrelatedqualityoflifeincopdpatientswithinoneyearrealworldanalysisbasedonclaimsdata |